FDA records linked by MedtechLedger show a single PMA number, P840064, carrying two linked entries for Alcon Laboratories: an original approval and a later 30-day notice. The applicant address on both records is in Fort Worth, Texas, and the advisory committee is listed as Ophthalmic. The manufacturer’s own professional documentation describes the same product family as ophthalmic viscosurgical devices used in cataract surgery, with chondroitin sulfate as a stated component. [1][2][4]
The original approval and its scope
P840064 was received by FDA on 29 November 1984 and approved on 30 April 1986, according to the agency record. The trade name listed is VISCOAT(TM)/DVOVISC/DISCOVISC OPHTHALMIC VISCOSURGICAL DEVICES, with generic name AID, SURGICAL, VISCOELASTIC, device class 3, product code LZP and regulation number 886.4275. The record carries a Federal Register notice date of 6 June 1986 and docket number 86M-0207. [2]
The same record identifies Alcon Laboratories as applicant at 6201 S. Fwy., Fort Worth, TX 76134, and lists the advisory committee as OP, described as Ophthalmic. FDA’s Devices@FDA entry for the PMA notes that the device has supplements and that the device description or indication may have changed, directing readers to the supplements for current information. [2][5]
A 2026 manufacturing-process notice
Supplement S094 to P840064 was received on 2 September 2026 and decided on 1 October 2026 with decision code OK30, a 30-day notice. The supplement type is listed as a 30-day notice and the reason as Process Change - Manufacturer/Sterilizer/Packager/Supplier. The applicant order statement describes a change in the endotoxin testing program for the subject ophthalmic viscosurgical devices, including test article preparation and individual component testing. [1]
The supplement record repeats the trade name VISCOAT Ophthalmic Viscosurgical Device; DUOVISC Ophthalmic Viscosurgical System; DISCOVISC Ophthalmic Viscosurgical, along with the same product code, regulation number and ophthalmic advisory committee as the original approval. The expedited review flag is marked N. [1]
How the collection breaks down
The linked collection for this applicant contains two PMA records, both under P840064. Across the full collection, decision counts are one OK30 and one APPR. Within the smaller record sample of two entries, the sample decision counts are likewise one OK30 and one APPR. These figures describe the linked filings as of the snapshot date and are not measures of total company portfolio, sales or safety performance. [1][2]
Product description from the manufacturer
Alcon’s professional page for ophthalmic viscosurgical devices states that OVDs with chondroitin sulfate lose viscosity at a slower rate during stress and readily adhere to ocular tissue, and it presents the devices under a heading about protecting what is important. The page also lists references, including a title on the protective effect of OVDs against hydrogen peroxide-induced oxidative damage and a clinical trial evaluation of Viscoat and Visthesia. Those statements are the manufacturer’s published claims, not FDA findings. [4]




